Clinical Study

Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (Guide-It)

Posted Date: Mar 19, 2014

  • Investigator: Stephanie Dunlap
  • Co-Investigator: Carol Knochelmann
  • Specialties: Cardiology, Cardiovascular Disease, Heart Failure, Heart Disease
  • Type of Study: Drug

The purpose of this study is to see if using the results of a blood test for NT-proBNP (a hormone released from the heart also known as a Biomarker) can help doctors decide the best drug treatment for patients who have heart failure (HF). Heart failure is a common disorder in which the heart cannot pump enough blood to meet the needs of the rest of the body. Common symptoms of heart failure include shortness of breath, swelling, and fatigue. Standard treatment for heart failure includes diuretics to control fluid, as well as drugs called "neurohormonal antagonists" (such as beta-blockers and ACE-inhibitors) that help the heart work more efficiently and prevent worsening of heart function. Typically, doctors adjust these medicines based on their clinical judgment about what doses and combination will work best for you. The researchers are testing whether the use of a blood test called NT-proBNP (which measures a hormone released by the heart) can help doctors do a better job of adjusting heart failure medicines over time than clinical judgment alone.

Criteria:

You Are Being Asked To Take Part In This Research Study Because You Have Been Admitted To The Hospital With Heart Failure And Are 18 Years Of Age Or Older.

Keywords:

Bnp, Congestive Heart Failure, Chf, Cardiomyopathy, Heart Failure

For More Information:

Carol Knochelmann
(513) 558-3016
carol.knochelmann@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.